Literature DB >> 8084500

Differential effects of chronic L-dopa treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine.

N Ogawa1, M Asanuma, Y Kondo, Y Kawada, M Yamamoto, A Mori.   

Abstract

Whether or not chronic L-dopa treatment (100 mg/kg, intraperitoneally (i.p.), twice daily for 4 weeks) alters lipid peroxidation in the brain as an indicator of neuronal damage was examined in normal mice and mice in which catecholamine (CA) neurons had been injured previously by the administration of 6-hydroxydopamine (6-OHDA), followed by recovery. In normal mice, chronic L-dopa treatment reduced the thiobarbituric acid reacting substances (TBARS) level, an indicator of lipid peroxidation, in the cerebral cortex. In contrast, in mice with CA neuronal injury induced by pretreatment with 6-OHDA, the chronic L-dopa treatment markedly increased the TBARS in the striatum and frontal cortex, despite recovery of the striatal dopamine levels similar to those in the control mice. These findings suggest that the long-term high-dose administration of L-dopa enhances the progression of neuronal damage in patients with injured CA neurons such as those with Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8084500     DOI: 10.1016/0304-3940(94)90603-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  9 in total

1.  Effects of zingerone [4-(4-hydroxy-3-methoxyphenyl)-2-butanone] and eugenol [2-methoxy-4-(2-propenyl)phenol] on the pathological progress in the 6-hydroxydopamine-induced Parkinson's disease mouse model.

Authors:  Hideaki Kabuto; Tomoko T Yamanushi
Journal:  Neurochem Res       Date:  2011-07-19       Impact factor: 3.996

2.  Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.

Authors:  G Walkinshaw; C M Waters
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

Review 3.  Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?

Authors:  M G Murer; R Raisman-Vozari; O Gershanik
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 4.  Levodopa therapy from the neuroprotection viewpoint. From a clinical outlook.

Authors:  Tomoyoshi Kondo
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

Review 5.  Methamphetamine Dysregulation of the Central Nervous System and Peripheral Immunity.

Authors:  Douglas R Miller; Mengfei Bu; Adithya Gopinath; Luis R Martinez; Habibeh Khoshbouei
Journal:  J Pharmacol Exp Ther       Date:  2021-09-17       Impact factor: 4.402

Review 6.  Elucidating the Beneficial Effects of Ginger (Zingiber officinale Roscoe) in Parkinson's Disease.

Authors:  Efthalia Angelopoulou; Yam Nath Paudel; Sokratis G Papageorgiou; Christina Piperi
Journal:  ACS Pharmacol Transl Sci       Date:  2022-09-07

Review 7.  Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.

Authors:  Masato Asanuma; Ikuko Miyazaki; Norio Ogawa
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

8.  1-Benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous neurotoxic compound, disturbs the behavioral and biochemical effects of L-DOPA: in vivo and ex vivo studies in the rat.

Authors:  Agnieszka Wąsik; Irena Romańska; Jerzy Michaluk; Małgorzata Kajta; Lucyna Antkiewicz-Michaluk
Journal:  Neurotox Res       Date:  2014-05-20       Impact factor: 3.911

Review 9.  Recent advances on the neuroprotective potential of antioxidants in experimental models of Parkinson's disease.

Authors:  Sushruta Koppula; Hemant Kumar; Sandeep Vasant More; Byung Wook Kim; In Su Kim; Dong-Kug Choi
Journal:  Int J Mol Sci       Date:  2012-08-23       Impact factor: 6.208

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.